Marinus Pharmaceuticals (MRNS) Investor & Analyst 2024 summary

Strategic vision and future plans

• Expanding ganaxolone (ZTALMY®) from CDKL5 deficiency disorder (CDD) into tuberous sclerosis complex (TSC), with a U.S. NDA filing targeted for April 2025 and topline Phase 3 TrustTSC data expected in early Q4 2024, leveraging a proven commercial model and infrastructure for rare epilepsies.

• Global expansion underway, with launches in Europe and China imminent, and partnerships in MENA and other regions to drive ex-U.S. milestones and royalty revenue.

• Investments in manufacturing and supply chain to support a five- to tenfold increase in production, ensuring readiness for global demand.

• Business development efforts target complementary compounds and a prodrug successor to ganaxolone, aiming for improved dosing, efficacy, and IP protection, with IND targeted by year-end 2025.

• Plans to pursue additional indications, including Lennox-Gastaut syndrome (LGS) and other developmental and epileptic encephalopathies (DEEs), with new clinical trials set to begin in the second half of 2025 and flexible clinical strategies.

Clinical development and scientific differentiation

• Ganaxolone’s unique mechanism targets both synaptic and extrasynaptic GABA-A receptors, offering broad-spectrum anti-seizure efficacy and minimal drug-drug interactions.

• Phase 2 and long-term extension data in TSC show sustained seizure reduction (median 56% at two years, 87% at 22-24 months) and favorable tolerability with revised titration.

• Phase 3 TrustTSC trial completed enrollment, with top-line data expected in early Q4 2024; trial design incorporates lessons from prior studies to optimize efficacy and minimize somnolence.

• Revised titration schedule reduces somnolence-related adverse events and improves patient retention, with high compliance and low discontinuation rates observed.

• The trial includes patients on concomitant therapies (Epidiolex, mTOR inhibitors), reflecting real-world practice and supporting broad label expansion.

Commercial execution and financial outlook

• ZTALMY achieved 87% revenue growth since Q2 2023, with 2024 full-year guidance of $33–$35 million, over 200 patients on active therapy, and 83% commercial payer coverage; all CDD patients have received coverage.

• TSC market is 6-7 times larger than CDD, with 12,700 addressable refractory patients; faster uptake expected due to easier diagnosis and established payer pathways.

• Commercial infrastructure is scalable, requiring only modest expansion for TSC; anticipated $200M+ annualized revenue within 18 months of TSC launch, with profitability targeted within 18 months.

• Combined commercial investment for CDD and TSC is expected to remain under $50M, with SG&A expenses projected below $100M and COGS at 10% of net price.

• Cash runway extends into Q2 2025, with $64.7M in cash and $58M in debt as of June 30, 2024; additional capital expected from ex-U.S. milestones and royalties.